What insurance policy changes affect code F11.19?

There are 2 tracked policy changes affecting code F11.19, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code F11.19?

Payers that have issued tracked updates for code F11.19 include: Aetna.

How do I get notified when code F11.19 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code F11.19. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code F11.19?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

F11.19 Insurance Policy Changes

ICD-10 F11.19 is officially defined as "Opioid abuse with unspecified opioid-induced disorder." code F11.19 is referenced in 2 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code F11.19 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Only a small number of policies match this filter. Check back as coverage expands.

Aetna · Identified Aug 18, 2026Medium impact
Ultra Rapid Detoxification (UROD) (CPB 0317, reviewed 2026-05-21)
Aetna considers ultra rapid detoxification (UROD) experimental, investigational, or unproven as a clinical detoxification treatment and for all other indications, because its effectiveness has not been established. The procedure induces opiate detoxification with a bolus of very high-dose naloxone under general anesthesia or heavy sedation, followed by a slow infusion of low-dose naloxone. There is a reported risk of serious adverse events, including death, with the use of anesthetics, and the policy's cited NICE guidance states that ultra-rapid detoxification under general anesthesia or heavy sedation must not be offered.
Aetna · Identified Aug 14, 2026Medium impact
Diagnosis of Vaginitis (CPB 0643, reviewed 2025-12-15)
Aetna considers several vaginitis tests medically necessary for women with symptoms of vaginitis, including nucleic acid amplification or DNA probe assays for trichomonas, Candida and Gardnerella for members with dysuria or symptoms of vaginitis, sialidase activity testing such as the BVBlue test, and pH and amine testing of vaginal fluid. Screening for Trichomonas vaginalis is considered medically necessary for women with risk factors such as HIV-positive status, new or multiple partners, a history of sexually transmitted diseases, exchange of sex for payment, injection drug use, or high-prevalence settings such as STD clinics and correctional facilities. A Pap smear for the diagnosis of Candida vulvo-vaginitis, routine screening for Candida and Gardnerella in asymptomatic women, the uBiome SmartJane screen, and the 27-organism vaginal pathogen panel from Bridge Diagnostics are considered experimental, investigational, or unproven because their effectiveness has not been established.

Watch F11.19

Get one email when a payer policy names F11.19, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Ultra Rapid Detoxification (UROD) (CPB 0317, reviewed 2026-05-21)

Diagnosis of Vaginitis (CPB 0643, reviewed 2025-12-15)

What insurance policy changes affect code F11.19?

Which payers have updated policy for code F11.19?

How do I get notified when code F11.19 policy changes?

Why do payers change policies for code F11.19?